Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Purpose-Driven Risk Assessment.

Lipscomb JC.

Toxicol Pathol. 2019 Oct 3:192623319875714. doi: 10.1177/0192623319875714. [Epub ahead of print]

PMID:
31581901
2.

The Impact of Scaling Factor Variability on Risk-Relevant Pharmacokinetic Outcomes in Children: A Case Study Using Bromodichloromethane (BDCM).

Kenyon EM, Lipscomb JC, Pegram RA, George BJ, Hines RN.

Toxicol Sci. 2019 Feb 1;167(2):347-359. doi: 10.1093/toxsci/kfy236.

PMID:
30252107
3.

FutureTox III: Bridges for Translation.

Juberg DR, Knudsen TB, Sander M, Beck NB, Faustman EM, Mendrick DL, Fowle JR 3rd, Hartung T, Tice RR, Lemazurier E, Becker RA, Fitzpatrick SC, Daston GP, Harrill A, Hines RN, Keller DA, Lipscomb JC, Watson D, Bahadori T, Crofton KM.

Toxicol Sci. 2017 Jan;155(1):22-31. doi: 10.1093/toxsci/kfw194. Epub 2016 Oct 25.

4.

The impact of variation in scaling factors on the estimation of internal dose metrics: a case study using bromodichloromethane (BDCM).

Kenyon EM, Eklund C, Lipscomb JC, Pegram RA.

Toxicol Mech Methods. 2016 Oct;26(8):620-626. Epub 2016 Oct 27.

PMID:
27595344
5.

Gaining acceptance for the use of in vitro toxicity assays and QIVIVE in regulatory risk assessment.

Meek ME, Lipscomb JC.

Toxicology. 2015 Jun 5;332:112-23. doi: 10.1016/j.tox.2015.01.010. Epub 2015 Jan 15. Review.

PMID:
25598226
6.

Correlating in vitro data to in vivo findings for risk assessment.

Bale AS, Kenyon E, Flynn TJ, Lipscomb JC, Mendrick DL, Hartung T, Patton GW.

ALTEX. 2014;31(1):79-90. doi: 10.14573/altex.1310011. Epub 2013 Nov 14.

7.

Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment.

Meek ME, Barton HA, Bessems JG, Lipscomb JC, Krishnan K.

Regul Toxicol Pharmacol. 2013 Jun;66(1):116-29. doi: 10.1016/j.yrtph.2013.03.005. Epub 2013 Mar 25.

PMID:
23535119
8.

Human health effects of trichloroethylene: key findings and scientific issues.

Chiu WA, Jinot J, Scott CS, Makris SL, Cooper GS, Dzubow RC, Bale AS, Evans MV, Guyton KZ, Keshava N, Lipscomb JC, Barone S Jr, Fox JF, Gwinn MR, Schaum J, Caldwell JC.

Environ Health Perspect. 2013 Mar;121(3):303-11. doi: 10.1289/ehp.1205879. Epub 2012 Dec 18. Review.

9.

Putative mechanisms of environmental chemical-induced steatosis.

Kaiser JP, Lipscomb JC, Wesselkamper SC.

Int J Toxicol. 2012 Nov-Dec;31(6):551-63. doi: 10.1177/1091581812466418. Epub 2012 Nov 29.

PMID:
23197488
10.

Application of an updated physiologically based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and mice.

Sasso AF, Schlosser PM, Kedderis GL, Genter MB, Snawder JE, Li Z, Rieth S, Lipscomb JC.

Toxicol Sci. 2013 Feb;131(2):360-74. doi: 10.1093/toxsci/kfs320. Epub 2012 Nov 9.

PMID:
23143927
11.

Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment.

Lipscomb JC, Haddad S, Poet T, Krishnan K.

Adv Exp Med Biol. 2012;745:76-95. doi: 10.1007/978-1-4614-3055-1_6. Review.

PMID:
22437814
12.

Identification of developmentally toxic drinking water disinfection byproducts and evaluation of data relevant to mode of action.

Colman J, Rice GE, Wright JM, Hunter ES 3rd, Teuschler LK, Lipscomb JC, Hertzberg RC, Simmons JE, Fransen M, Osier M, Narotsky MG.

Toxicol Appl Pharmacol. 2011 Jul 15;254(2):100-26. doi: 10.1016/j.taap.2011.02.002. Epub 2011 Feb 4. Review.

PMID:
21296098
13.

Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements.

Mazur CS, Kenneke JF, Hess-Wilson JK, Lipscomb JC.

Drug Metab Dispos. 2010 Dec;38(12):2232-8. doi: 10.1124/dmd.110.034819. Epub 2010 Aug 24.

PMID:
20736320
14.

Haloacetonitriles: metabolism and toxicity.

Lipscomb JC, El-Demerdash E, Ahmed AE.

Rev Environ Contam Toxicol. 2009;198:169-200. doi: 10.1007/978-0-387-09647-6_5. Review.

PMID:
19253036
15.

Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling.

Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A.

Drug Metab Dispos. 2008 Dec;36(12):2405-9. doi: 10.1124/dmd.108.021311. Epub 2008 Sep 5.

PMID:
18775982
16.

Approaches for applications of physiologically based pharmacokinetic models in risk assessment.

Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Lipscomb JC, Schlosser P, Chiu WA, Krishnan K.

J Toxicol Environ Health B Crit Rev. 2008 Aug;11(7):519-47. doi: 10.1080/10937400701724337. Review.

PMID:
18584453
17.

In vitro measurements of metabolism for application in pharmacokinetic modeling.

Lipscomb JC, Poet TS.

Pharmacol Ther. 2008 Apr;118(1):82-103. doi: 10.1016/j.pharmthera.2008.01.006. Epub 2008 Feb 15. Review.

PMID:
18374419
18.

Age-dependent partition coefficients for a mixture of volatile organic solvents in Sprague-Dawley rats and humans.

Mahle DA, Gearhart JM, Grigsby CC, Mattie DR, Barton HA, Lipscomb JC, Cook RS.

J Toxicol Environ Health A. 2007 Oct;70(20):1745-51.

PMID:
17885931
19.

Mode of action as a determining factor in additivity models for chemical mixture risk assessment.

Lambert JC, Lipscomb JC.

Regul Toxicol Pharmacol. 2007 Dec;49(3):183-94. Epub 2007 Jul 24. Review.

PMID:
17804132
20.

In vitro metabolism of the fungicide and environmental contaminant trans-bromuconazole and implications for risk assessment.

Mazur CS, Kenneke JF, Tebes-Stevens C, Okino MS, Lipscomb JC.

J Toxicol Environ Health A. 2007 Jul;70(14):1241-50.

PMID:
17573638
21.

Predicting age-appropriate pharmacokinetics of six volatile organic compounds in the rat utilizing physiologically based pharmacokinetic modeling.

Rodriguez CE, Mahle DA, Gearhart JM, Mattie DR, Lipscomb JC, Cook RS, Barton HA.

Toxicol Sci. 2007 Jul;98(1):43-56. Epub 2007 Apr 10.

PMID:
17426107
22.

Evaluation of physiologically based pharmacokinetic models for use in risk assessment.

Chiu WA, Barton HA, DeWoskin RS, Schlosser P, Thompson CM, Sonawane B, Lipscomb JC, Krishnan K.

J Appl Toxicol. 2007 May-Jun;27(3):218-37. Review.

PMID:
17299829
23.

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2007 Jan;8(1):33-45. Review.

PMID:
17266522
24.

Issues in the pharmacokinetics of trichloroethylene and its metabolites.

Chiu WA, Okino MS, Lipscomb JC, Evans MV.

Environ Health Perspect. 2006 Sep;114(9):1450-6. Review.

25.

A feasibility study of cumulative risk assessment methods for drinking water disinfection by-product mixtures.

Teuschler LK, Rice GE, Wilkes CR, Lipscomb JC, Power FW.

J Toxicol Environ Health A. 2004 Apr 23-May 28;67(8-10):755-77.

PMID:
15192867
26.

The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform.

Lipscomb JC, Barton HA, Tornero-Velez R, Evans MV, Alcasey S, Snawder JE, Laskey J.

J Toxicol Environ Health A. 2004 Apr 9;67(7):537-53.

PMID:
15129551
27.

Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.

Lipscomb JC, Meek ME, Krishnan K, Kedderis GL, Clewell H, Haber L.

Toxicol Mech Methods. 2004;14(3):145-58. doi: 10.1080/15376520490429382.

PMID:
20021141
28.

Application of QSTRs in the selection of a surrogate toxicity value for a chemical of concern.

Moudgal CJ, Venkatapathy R, Choudhury H, Bruce RM, Lipscomb JC.

Environ Sci Technol. 2003 Nov 15;37(22):5228-35.

PMID:
14655712
29.

The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans.

Lipscomb JC, Teuschler LK, Swartout J, Popken D, Cox T, Kedderis GL.

Risk Anal. 2003 Dec;23(6):1221-38.

PMID:
14641897
30.

Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.

Kedderis GL, Lipscomb JC.

Toxicol Ind Health. 2001 Jun;17(5-10):315-21.

PMID:
12539878
31.

Variance of Microsomal Protein and Cytochrome P450 2E1 and 3A Forms in Adult Human Liver.

Lipscomb JC, Teuschler LK, Swartout JC, Striley CA, Snawder JE.

Toxicol Mech Methods. 2003;13(1):45-51. doi: 10.1080/15376510309821.

PMID:
20021182
32.
33.

Incorporating human interindividual biotransformation variance in health risk assessment.

Lipscomb JC, Kedderis GL.

Sci Total Environ. 2002 Apr 8;288(1-2):13-21.

PMID:
12013540
34.

Physiologically based pharmacokinetic modeling of the lactational transfer of methylmercury.

Byczkowski JZ, Lipscomb JC.

Risk Anal. 2001 Oct;21(5):869-82.

PMID:
11798123
35.

Cold and cryopreservation of monkey liver slices.

Fisher RL, Hasal SJ, Lipscomb JC, Gandolfi AJ, Brendel K.

Toxicol Mech Methods. 2002;12(2):119-33. doi: 10.1080/10517230290075350.

PMID:
20021197
37.
38.

Metabolism of trichloroethylene.

Lash LH, Fisher JW, Lipscomb JC, Parker JC.

Environ Health Perspect. 2000 May;108 Suppl 2:177-200. Review.

39.

A multiple-purpose design approach to the evaluation of risks from mixtures of disinfection by-products.

Teuschler LK, Gennings C, Stiteler WM, Hertzberg RC, Colman JT, Thiyagarajah A, Lipscomb JC, Hartley WR, Simmons JE.

Drug Chem Toxicol. 2000 Feb;23(1):307-21. Erratum in: Drug Chem Toxicol 2000 Aug;23(3):511.

PMID:
10711404
40.

Glutathione conjugation of trichloroethylene in human liver and kidney: kinetics and individual variation.

Lash LH, Lipscomb JC, Putt DA, Parker JC.

Drug Metab Dispos. 1999 Mar;27(3):351-9.

PMID:
10064565
41.

In vitro to in vivo extrapolation for trichloroethylene metabolism in humans.

Lipscomb JC, Fisher JW, Confer PD, Byczkowski JZ.

Toxicol Appl Pharmacol. 1998 Oct;152(2):376-87.

PMID:
9853006
42.

Covalent binding of trichloroethylene to proteins in human and rat hepatocytes.

Griffin JM, Lipscomb JC, Pumford NR.

Toxicol Lett. 1998 May;95(3):173-81.

PMID:
9704819
43.

Combustion products from advanced composite materials.

Lipscomb JC, Kuhlmann KJ, Cline JM, Larcom BJ, Peterson RD, Courson DL.

Drug Chem Toxicol. 1997 Nov;20(4):281-92.

PMID:
9433657
44.

The role of mouse intestinal microflora in the metabolism of trichloroethylene, an in vivo study.

Moghaddam AP, Abbas R, Fisher JW, Lipscomb JC.

Hum Exp Toxicol. 1997 Nov;16(11):629-35.

PMID:
9426363
45.

Chloral hydrate formation in the Japanese medaka minnow.

Lipscomb JC, Buttler GW, Confer PD.

Ann Clin Lab Sci. 1997 Mar-Apr;27(2):157-62.

PMID:
9098516
46.

Cytochrome P450-dependent metabolism of trichloroethylene: interindividual differences in humans.

Lipscomb JC, Garrett CM, Snawder JE.

Toxicol Appl Pharmacol. 1997 Feb;142(2):311-8.

PMID:
9070354
47.

Formation of dichloroacetic acid by rat and mouse gut microflora, an in vitro study.

Moghaddam AP, Abbas R, Fisher JW, Stavrou S, Lipscomb JC.

Biochem Biophys Res Commun. 1996 Nov 12;228(2):639-45.

PMID:
8920962
48.

A species comparison of chloral hydrate metabolism in blood and liver.

Lipscomb JC, Mahle DA, Brashear WT, Garrett CM.

Biochem Biophys Res Commun. 1996 Oct 14;227(2):340-50.

PMID:
8878519
49.
50.

Toxicant-induced alterations in two-dimensional electrophoretic patterns of hepatic and renal stress proteins.

Witzmann FA, Fultz CD, Lipscomb JC.

Electrophoresis. 1996 Jan;17(1):198-202.

PMID:
8907540

Supplemental Content

Loading ...
Support Center